跳至主要内容
临床试验/NCT05793424
NCT05793424尚未招募不适用

Establishment of a CSF Bank for the Development of Biomarkers of Smooth Muscle Cell Damage in Monogenic Cerebral Small Vessel Disease CSF-cSVD-biobank -- Constitution d'Une Banque de LCR Pour le développement de Biomarqueurs d'Atteinte Des Cellules Musculaires Lisses Dans Les Pathologies Micro-vasculaires cérébrales monogéniques CSF-cSVD-biobank

Assistance Publique - Hôpitaux de Paris0 个研究点目标入组 90 人开始时间: 2023年3月最近更新:
适应症

试验速览

阶段
不适用
状态
尚未招募
入组人数
90
主要终点
Differential CSF proteins

研究概览

简要总结

The main objective of this research is to obtain biological markers of smooth muscle cells dysfunction or degeneration in cerebral small vessel diseases.

The aim of this research is therefore to build up a biocollection of CSF and blood samples from 1) patients with CADASIL disease (the most common form of cSVD) responsible for an accumulation of the NOTCH3 protein in the microvessel wall, 2) patients with other forms of monogenic cSVD (rarer) which are not responsible for an accumulation of this protein despite the damage to the smooth muscle cells of the vessel wall and 3) control patients without cSVD, collected in the context of care.

This bio-collection will allow the identification and assay of markers testifying to the damage of the smooth muscle cells (SMC) in different types of cSVD of hereditary origin, the first of which will be the soluble NOTCH3 protein.

研究设计

研究类型
Observational
观察模型
Case Control
时间视角
Other

入排标准

年龄范围
18 Years 至 80 Years(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Patients aged between 18 and 80 years at the time of inclusion
  • Diagnosis confirmed by detection of a pathogenic mutation in the NOTCH3 gene characteristic of CADASIL, or in another gene responsible for other forms of monogenic cSVD (such as COL4A1, COL4A2, HTRA1).
  • Beneficiary of a social security system
  • Having given their written consent
  • Non inclusion Criteria:
  • Contraindication to lumbar puncture:
  • Haemostasis disorder (severe thrombocytopenia <60,000/mm3, PT abnormalities, INR>1.5 and/or aPTT>1.5) or anticoagulant use.
  • Spinal plaque in or near the lumbar region (surgery) that may interfere with CSF collection
  • Behavioural disorder that may interfere with the sampling process
  • Intracranial process, intracranial hypertension or risk of involvement on imaging
  • Skin lesions (inflammation or infection of any kind) or developmental abnormality (myelomeningocele) adjacent to the puncture site
  • Person referred to in articles L. 1121-5 to L. 1121-8 and L. 1122-12 of the public health code, defined as :
  • Pregnant, parturient or breastfeeding woman
  • Person deprived of liberty by judicial or administrative decision
  • Person hospitalised without consent and not subject to a legal protection measure, and person admitted to a health or social establishment for purposes other than research
  • Person of full age subject to a legal protection measure (guardianship, curators or safeguard of justice), person of full age unable to express their consent and not subject to a protection measure
  • Person subject to an exclusion period for another research
  • Patients participating in other interventional research
  • Contraindication to lumbar puncture:
  • Haemostasis disorder (severe thrombocytopenia <60,000/mm3, PT abnormalities, INR>1.5 and/or aPTT>1.5) or anticoagulant use.
  • Spinal plaque in or near the lumbar region (surgery) that may interfere with CSF collection
  • Spinal plaque (surgery)
  • Behavioural disorder that may interfere with the sampling process
  • Intracranial process, intracranial hypertension or risk of involvement on imaging
  • Skin lesions (psoriasis, infection....)inflammation or infection of any kind) or developmental abnormality (myelomeningocele) adjacent to the puncture site
  • Person referred to in articles L. 1121-5 to L. 1121-8 and L. 1122-12 of the public health code, defined as
  • Pregnant, parturient or breastfeeding woman
  • Person deprived of liberty by judicial or administrative decision
  • Person hospitalised without consent and not subject to a legal protection measure, and person admitted to a health or social establishment for purposes other than research
  • Person of full age subject to a legal protection measure (guardianship, curators or safeguard of justice), person of full age unable to express their consent and not subject to a protection measure
  • Person subject to an exclusion period for another research
  • Patients participating in other interventional research
  • For control patients ( selection after CSF sampling):
  • Inclusion criteria :
  • Subject aged 18-80 years at the time of inclusion
  • Imaging done: strictly normal CT scan OR MRI showing no abnormality suggestive of cSVD
  • Beneficiary of a social security system
  • Having had CSF and blood samples taken as part of the treatment
  • Agreement to use blood and CSF samples remainders for research purposes (information and non-opposition).
  • Women who were pregnant at the time the samples were taken will not be offered to participate in the study
  • Non inclusion criteria :
  • Any previously identified intracranial vascular pathology requiring specific management (vasculitis, acute reversible angiopathy, severe intracranial atheroma)
  • Acute or chronic infectious disease (meningitis or meningoencephalitis)
  • Known pregnancy
  • Persons participating in other interventional research
  • Preparation and freezing time for blood and CSF samples is more than 4 hours

排除标准

  • 未提供

结局指标

主要结局

Differential CSF proteins

时间窗: At inclusion

Differential ELISA determination of CSF proteins between monogenic cSVD patients and controls

次要结局

  • Correlation blood and CSF(At inclusion)
  • Effect of age on blood(At inclusion)
  • Differential blood proteins(At inclusion)
  • Link between CSF protein assays and Rankin(At inclusion)
  • Number(At inclusion)
  • Link between CSF protein assays and strokes(At inclusion)
  • Link between blood protein assays and MMSE(At inclusion)
  • Effect of age on CSF(At inclusion)
  • Link between blood protein assays and strokes(At inclusion)
  • Link between blood protein assays and Rankin(At inclusion)
  • Link between CSF protein assays and MMSE(At inclusion)

研究者

申办方类型
Other
责任方
Sponsor

相似试验